Advertisement

Topics

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

2016-10-05 00:23:21 | BioPortfolio

Summary

The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of MT-3995 in patients with NASH.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

NASH

Intervention

MT-3995, Placebo

Location

Investigational site
Kanagawa
Japan

Status

Recruiting

Source

Mitsubishi Tanabe Pharma Corporation

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-10-05T00:23:21-0400

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

This study aims to evaluate the safety and efficacy of MT-3995 administered over the longer term, following MT-3995-J05 study.

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

The purpose of this study is to evaluate the efficacy of MT-3995 in subjects with diabetic nephropathy, compared with placebo, using urine albumin- to-creatinine ratio (UACR) in the first ...

Mass Balance Study of MT-3995

The purpose of this study is to investigate the absorption, metabolism and excretion of MT-3995 in healthy subjects.

Drug Interaction Study of Warfarin and MT-3995

The purpose of this study is to evaluate the effects of MT-3995 on the PK of warfarin

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

PubMed Articles [1021 Associated PubMed Articles listed on BioPortfolio]

Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.

This paper reports the protocol of a randomised, double-blind, placebo-controlled study to test the efficacy, safety, and tolerability of lubiprostone (LUB) vs. placebo on suppressing gut permeability...

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.

The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The ai...

Nonalcoholic steatohepatitis in posttransplantation liver: Review article.

Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and ...

A Single Dose Of Oral Atp Supplementation Improves Performance And Physiological Response During Lower Body Resistance Exercise In Recreational Resistance Trained Males.

The aim of this study was to investigate the acute effect of ATP supplementation on performance and physiological responses during resistance exercise in recreationally resistance trained males. Eleve...

The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and overweight. It has a broad spectrum of clinical and histological presentations, such as steatosis, inflammation (kno...

Medical and Biotech [MESH] Definitions

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

More From BioPortfolio on "Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial